InferVision shows strength in the AI medical industry with access to major markets. [Photo/WeChat account: hefeigaoxinfabu]

China's National Medical Products Administration (NMPA) officially granted InferVision's AI-assisted pulmonary nodule products class III certification on Nov 13, the first such approval in AI medicine for lung diseases.

The company has become the first AI medical company in the world to be certified by the EU's CE, Japan's PMDA, the US FDA, and China's NMPA, giving it access to most of the world's major medical markets.

These four regions have strict regulations and high barriers for AI medical products, and InferVision's access to these markets has made it a prominent company in the global AI medical industry.

InferVision's assistance system for pulmonary nodule detection in CT images met NMPA's requirements for strict clinical trials, a wide range of applications, a high technology threshold, and a large potential market.

The company became the first in the world to receive both FDA and PMDA certifications for AI-assisted chest and lung CTs at the beginning of this year.

These certifications are a testament to InferVision's R&D strength and will help the company expand international cooperation and strengthen ties with more than 60 overseas medical institutions.